U.S. research roundup: Alnylam Pharmaceuticals, Carvana, MongoDB
CVNA•Analysts revised ratings and price targets for U.S.-listed companies, including a target cut for Alnylam to $369 from $375, a split-adjusted Carvana target of $90, and three MongoDB target cuts.
1. Selected analyst actions
Oppenheimer adjusted its Carvana price target to $90 from $450 to reflect a 5-for-1 stock split. D.A. Davidson, Stephens and Stifel cut their MongoDB price targets to $415 from $465, $372 from $398 and $385 from $465, respectively. JP Morgan cut its Alnylam target to $369 from $375.
2. Other notable changes
Piper Sandler raised its Microsoft target to $610 from $550. Bernstein initiated coverage of Lumentum with an outperform rating and a $1,220 target. Citigroup cut Moderna to sell from neutral while raising its target to $80 from $60.
